In addition, IL-13Rα2, a restrictive receptor for IL-13, is overexpressed in the majority of GBM patients, making it a prime candidate for chimeric antigen receptor (CAR) T-cell therapy [147]. This evidence concerns the gene IL13RA2 and glioblastoma.